🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Cencora, Inc. COR SPXR3KPHARMA

Healthcare · Medical Distribution · United States
https://www.cencora.com
Company Profile ↓
$330.95
+14.57% 1Y
Mkt Cap$63.15B
P/E24.59
P/B18.35
Div. Yield0.74%
52W High$372.53
52W Low$251.67
Book Value$17.46
EPS (TTM)$13.46

Company Overview

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 96.9%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 21.0%.

Reasonable Valuation

Trades at a P/E of 24.6, below the sector median of 25.2.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Sep 2025 Revenue of $321.33B (+9.3% YoY); net profit $1.55B.
  • Trailing 12 Months Year-on-year growth — revenue +5.1%, earnings +11.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 9.8%, profit CAGR 7.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:9.79%
1 Year:5.10%

Compounded Profit Growth

5 Years:7.30%
1 Year:11.90%

Stock Price Performance

1 Year:+14.57%
6 Months:-7.28%
3 Months:+20.56%
1 Month:+2.03%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 66% of range
$251.67 $372.53
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)59.25 · Neutral
Price Performance
1M+2.03%
3M+20.56%
6M-7.28%
1Y+14.57%
Valuation vs Sector

P/E of 24.59 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 96.9%.
  • Healthy ROCE of 21.0%.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
24.59
Industry PE
25.17
Forward P/E
16.69
PEG Ratio
0.67
Book Value
$17.46
Price to Book
18.35
P/S
0.18
EV/EBITDA
13.16
Dividend Yield
0.74%

Growth (CAGR)

Revenue 5Y
9.79%
Profit 5Y
7.30%
Revenue (YoY)
5.10%
Earnings (YoY)
11.90%

Profitability & Returns

ROCE
20.96%
ROE
96.87%
ROA
3.56%
Profit Margin
0.79%
Op Margin
1.41%
Gross Margin
3.96%
EPS (Latest Qtr)
$3.94
EPS (TTM)
$13.46

Balance Sheet & Liquidity

Debt/Equity
4.47
Quick Ratio
0.48
Current Ratio
0.94
Debt
$14.46B
Total Assets
$83.81B
Current Assets
$53.14B
Working Capital
$-5.58B

Ownership

Promoter Holding
4.30%
Chg in Prom Hold
-0.01%
FII / Inst Holding
99.64%
Chg in FII Hold
0.04%

Financial Snapshot

Enterprise Value
$63.15B
Total Revenue (TTM)
$332.77B
EBITDA
$5.55B
Free Cash Flow
$2.04B
Operating Cash Flow
$4.82B
Shares Outstanding
190.83M
Gross Margin
3.96%
Payout Ratio
17.45%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 COR Cencora, Inc. SPXR3KPHARMA 330.95 24.59 $63.15B 0.74% 20.96% 96.87% 9.79% 7.30%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Dec 2021Mar 2022Jun 2022Dec 2022Mar 2023Jun 2023Dec 2023Mar 2024Jun 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 35.47B36.71B35.70B36.88B37.56B38.17B37.15B38.71B39.12B40.47B41.03B43.14B43.30B45.39B43.32B45.24B45.64B47.86B47.42B45.37B49.24B52.52B49.15B53.41B59.63B57.72B60.06B62.85B63.46B66.95B72.25B68.41B74.24B-75.45B80.66B83.73B85.93B78.36B84.75B
Cost of Revenue ----------------------------------72.39B77.76B80.77B82.86B74.77B-
Gross Profit 973.57M964.88M1.08B1.11B1.12B1.04B1.26B1.08B1.17B1.11B1.26B1.21B1.03B1.30B1.42B1.23B1.18B1.23B1.39B1.23B1.35B1.45B1.53B1.89B2.06B2.24B2.02B2.15B2.30B2.26B2.47B2.54B2.41B-3.06B2.91B2.95B3.07B3.59B3.61B
Operating Expenses ----------------------------------1.86B1.93B2.01B2.06B2.23B-
Operating Income 538.48M-178.14M950.48M528.63M224.80M399.99M624.98M170.38M-135.00M418.97M481.42M389.19M154.10M477.82M47.56M406.69M179.84M263.44M309.51M404.83M-6.11B547.23M624.35M620.73M644.40M780.16M487.30M633.14M560.52M670.13M822.88M553.26M672.48M-1.20B980.24M945.94M1.02B1.36B1.12B
EBITDA ----------------------------------1.32B1.27B186.31M1.07B2.51B-
Interest Expense ----------------------------------132.32M116.90M109.36M93.36M154.34M-
Pretax Income ----------------------------------928.66M896.28M-187.04M708.64M2.09B-
Tax Provision ----------------------------------211.24M206.53M146.03M142.51M459.04M-
Net Income 363.12M329.64M603.45M349.15M145.69M247.25M411.47M50.35M-344.59M861.85M287.45M275.81M233.29M393.65M27.14M301.96M132.62M187.64M960.28M289.44M-4.85B374.85M435.27M292.12M449.11M548.01M406.96M479.75M435.40M479.58M601.50M420.77M483.46M-717.87M687.40M-339.70M559.65M1.64B763.52M
Diluted EPS 1.561.452.681.550.641.111.860.23-1.583.901.291.251.071.840.131.430.630.904.641.41-23.741.812.101.402.132.591.922.332.132.352.982.092.42-3.683.52-1.752.878.403.94

Profit & Loss (Annual)

Figures in USD.

Metric Sep 2007Sep 2008Sep 2009Sep 2010Sep 2011Sep 2012Sep 2013Sep 2014Sep 2015Sep 2016Sep 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Revenue 65.67B70.19B71.76B77.78B78.70B78.08B87.96B119.57B135.96B146.85B153.14B167.94B179.59B189.89B-238.59B262.17B293.96B321.33B
Cost of Revenue ---------------230.29B253.21B284.05B309.85B
Gross Profit 2.22B2.05B2.10B2.33B2.46B2.63B2.51B2.98B3.53B4.27B4.55B4.61B5.14B5.19B-8.30B8.96B9.91B11.48B
Operating Expenses ---------------5.54B6.27B6.75B7.54B
Operating Income 788.74M827.86M883.75M1.09B1.19B1.30B898.40M782.09M422.22M1.53B1.06B1.44B1.11B-5.14B-2.75B2.69B3.16B3.93B
EBITDA ---------------3.10B3.37B3.37B3.75B
Interest Expense ---------------210.67M228.93M248.68M419.75M
Pretax Income ---------------2.18B2.16B2.00B2.26B
Tax Provision ---------------516.52M428.26M484.70M690.52M
Net Income 469.17M250.56M503.40M636.75M706.62M718.99M433.71M274.23M-138.16M1.43B364.48M1.66B855.37M-3.41B-1.70B1.75B1.51B1.55B
Diluted EPS 1.250.771.662.222.542.801.841.16-0.636.321.647.534.04-16.65-8.048.537.537.96

Balance Sheet (Annual)

Figures in USD.

Metric Sep 2006Sep 2007Sep 2008Sep 2009Sep 2010Sep 2011Sep 2012Sep 2013Sep 2014Sep 2015Sep 2016Sep 2017Sep 2018Oct 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Total Assets --12.22B13.57B14.43B14.98B15.44B18.92B21.53B27.96B33.64B35.32B37.67B-39.17B44.27B-56.56B62.56B67.10B76.59B
Current Assets -----------------39.59B42.80B47.72B52.24B
Cash & Equivalents 1.26B640.20M878.11M1.01B1.66B1.83B1.07B1.23B1.81B2.17B2.74B2.44B2.49B-3.37B4.60B-3.39B2.59B3.13B4.36B
Inventory -----------------15.56B17.45B19.00B20.49B
Receivables -----------------18.45B20.91B23.87B25.23B
Total Liabilities -----------------56.49B61.89B66.31B74.84B
Current Liabilities --8.17B9.48B9.91B10.88B11.27B14.87B17.25B21.58B25.28B26.82B27.87B-29.58B33.85B-43.48B48.83B54.28B57.82B
Long Term Debt --1.19B1.18B1.34B972.86M1.40B1.40B2.00B3.49B3.58B3.43B4.16B400.00M4.03B3.62B-4.63B4.15B3.81B7.54B
Total Debt -----------------5.70B4.79B4.39B7.66B
Total Equity 4.14B3.10B2.71B2.72B2.95B2.87B2.45B2.31B1.94B616.39M2.13B2.06B2.93B-2.88B-1.02B--211.56M522.00M645.94M1.51B
Shares Outstanding -----------------292.70M294.82M296.17M297.40M

Cash Flows (Annual)

Figures in USD.

Metric Sep 2007Sep 2008Sep 2009Sep 2010Sep 2011Sep 2012Sep 2013Sep 2014Sep 2015Sep 2016Sep 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Operating Cash Flow 1.21B737.07M783.76M1.11B1.17B1.31B788.12M1.46B3.92B3.18B1.50B1.41B2.34B2.21B2.67B2.70B3.91B3.48B3.88B
Investing Cash Flow -674.44M163.42M-148.35M-184.37M-212.42M-947.95M117.26M-384.15M-2.93B-3.17B-498.04M-1.11B-375.83M-379.87M-6.14B-368.44M-2.60B-618.10M-4.98B
Financing Cash Flow -1.15B-662.58M-504.16M-275.44M-787.72M-1.12B-740.99M-502.99M-632.13M565.07M-1.31B-242.87M-1.09B-603.62M1.95B-1.75B-2.22B-2.33B2.25B
Capital Expenditure -111.28M-137.31M-145.84M-176.47M-156.14M-133.29M-202.45M-264.46M-231.59M-464.62M-466.40M-336.41M-310.22M-369.68M-438.22M-496.32M-458.36M-487.17M-667.98M
Free Cash Flow 1.10B599.76M637.93M932.15M1.01B1.17B585.67M1.20B3.69B2.71B1.04B1.07B2.03B1.84B2.23B2.21B3.45B3.00B3.21B
Share Buybacks 1.43B679.68M450.35M470.36M840.58M1.16B484.18M753.93M1.86B2.27B329.93M639.24M674.03M420.45M82.15M483.70M1.18B1.49B435.47M

Ratios (Annual)

Figures in %.

Metric Sep 2007Sep 2008Sep 2009Sep 2010Sep 2011Sep 2012Sep 2013Sep 2014Sep 2015Sep 2016Sep 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Gross Margin % 3.4%2.9%2.9%3.0%3.1%3.4%2.9%2.5%2.6%2.9%3.0%2.7%2.9%2.7%-3.5%3.4%3.4%3.6%
Operating Margin % 1.2%1.2%1.2%1.4%1.5%1.7%1.0%0.7%0.3%1.0%0.7%0.9%0.6%-2.7%-1.2%1.0%1.1%1.2%
Net Margin % 0.7%0.4%0.7%0.8%0.9%0.9%0.5%0.2%-0.1%1.0%0.2%1.0%0.5%-1.8%-0.7%0.7%0.5%0.5%
ROE % 15.1%9.2%18.5%21.6%24.6%29.3%18.8%14.1%-22.4%67.1%17.7%56.5%29.7%334.5%--803.0%334.3%233.6%103.1%
ROCE % -20.4%21.6%24.1%29.0%31.2%22.2%18.3%6.6%18.3%12.5%14.7%11.6%-49.3%-21.0%19.6%24.6%21.0%

Shareholding Pattern

Insiders
4.30%
Institutions
99.64%
Public Float
104.12%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 9.54% 18.21M $5.87B
2 Vanguard Capital Management LLC 6.49% 12.38M $3.99B
3 Vanguard Portfolio Management LLC 5.04% 9.61M $3.10B
4 State Street Corporation 4.86% 9.27M $2.99B
5 T. Rowe Price Investment Management, Inc. 3.88% 7.41M $2.39B
6 Price (T.Rowe) Associates Inc 3.74% 7.13M $2.30B
7 JPMORGAN CHASE & CO 3.11% 5.94M $1.91B
8 Geode Capital Management, LLC 2.86% 5.45M $1.76B
9 Boston Partners 2.55% 4.87M $1.57B
10 Wellington Management Group, LLP 2.39% 4.56M $1.47B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for COR

Google News Fri, 04 Sep 2026

Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNUkFlVjYzQmJVbWQ4NEE1NnhiQV8zaFVnLWc5RURDblJPYjRpbHU3NXRlclRTd1RGc1YtRWRYSGliZUwzSnNMTGphOFhDNTNpOXk3UFl6em1nVkZ1TjN3YWEyZ3hmSEdzZW9TX1NrSmdBR3VUcFhKN3FIUnZqTGFoZklGU0RWeGJ1V2tGTV…

Google News Sun, 06 Sep 2026

Why Cencora (COR) Is Getting Attention Today - simplywall.st

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNaTAwN1pHX21FUUpCVzg1eVFoLUZnalNrY1RnU0cxVjNrTU81d0RRQ1V1d3lVWjJpdEl1dnRvTGpoc2FvWXRhMDBvNDg1SHpLV1RqLXlfcHpHMV9kME5SLUQ3ZHg3R19zdTVSb1NZYjFfZFNpbWhUV09MT25odWdLVGVXcVZkVGROQXBuNU…

Google News Fri, 04 Sep 2026

Here's Why You Should Retain Cencora Stock in Your Portfolio for Now - TradingView

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNMlZLZ0Z3MkFfOEZCT2pLZlNFVWFNa3FOZVlWbjYtNnZLZDNHcG9lbm95M083eTNqX0NlWnlTbHQ5RVJRRUZhTzJ2Rl9UWFF0Q2NYSm5iQXd2YmI1OWRfOHpvTEtfREQzVmFfQUhZUnB6ejVQREcwRkxGUl95U3EzYUxSb0NEV2VWMzVDan…

Google News Fri, 04 Sep 2026

Former Cencora (NYSE: COR) leader lines up another stock sale - Stock Titan

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxOeDNuTUZZb2UwcDZ2aGhGTkxQNGJWSVMxdWJQdGFfbHpiUlhoaVB0czIyUHRtOVhYbnE1MkNTY3V2Q1pucFdWTlFKQ09oWFdEaWotTTNDR3ExTV9rYmptQUwtdXJYeHNnSG5sdW9NN2EyYzlKdkNCRVlObGxaTkIzV3h5bFdoZGtUcm5uV2…

Google News Sat, 05 Sep 2026

(COR) Risk Channels and Responsive Allocation - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQOExZbjMzLVJQeXVKdVFhTEV5dzc3NV9EZzBxYXNROUx4Vkk3alRncF9sTVpNd1hVMnZNcVNJcXppYXl0VUUtWkljaGNrTDF1T21lSXlJLWJjLUpoNUkwRmQ3N1ZuZmRvN1NZSUYtOWM4eUljQTdaYWlvZndhZHRSeFN4eGRWYzVmeFJBdW…

Google News Fri, 04 Sep 2026

Is Cencora (COR) Still Undervalued On Higher 2026 Guidance And Strong Q3 Earnings? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQaC01Q2kyRWRkQ1pJWDRNYnJaSmFwZEljQjJ0c0NwaGFzNi1JUmxpaFFmcTJvVGUweFJfRDQzOUxHa1ZnUXlxS2JBLXJSTzA0Skt1dXVid05Gb3dWQzhyLWpBTGRSZUVEYmxHb3pFN3llTFNvb19jV0VnaGgtQ3FmMW9YZWZSSEdMdk56aj…

COR — Frequently Asked Questions

What is the current share price of Cencora, Inc. (COR)?

As of 2026-09-07 16:24 PDT, Cencora, Inc. (COR) trades at $330.95 on NYSE. Its 52-week range is $251.67 to $372.53.

What is the market capitalisation of COR?

Cencora, Inc. (COR) has a market capitalisation of $63.15B on NYSE.

What is the P/E ratio of COR?

COR trades at a trailing price-to-earnings (P/E) ratio of 24.59. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 18.35.

Does COR pay a dividend?

Cencora, Inc. (COR) currently offers a dividend yield of 0.74%.

What is the return on equity (ROE) of COR?

COR has a return on equity (ROE) of 96.87%. Its return on capital employed (ROCE) is 20.96%.

Is COR a good stock to buy?

This page provides a data-driven analysis of Cencora, Inc. (COR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space